Liste des publications

Mbatchi LC, Gassiot M, Pourquier P, Goberna A, Mahammedi H, Mourey L, Joly F, Lumbroso S, Evrard A, Houede N. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Jul 4. doi: 10.1007/s00280- 017-3379-5. [Epub ahead of print]


Cherradi S, Ayrolles-Torro A, Vezzo-Vié N, Gueguinou N, Denis V, Combes E, Boissière F, Busson M, Canterel-Thouennon L, Mollevi C, Pugnière M, Bibeau F, Ychou M, Martineau P, Gongora C, Del Rio M. Antibody targeting of claudin-1 as a potential colorectal cancer therapy. J Exp Clin Cancer Res. 2017 Jun 28;36(1):89. doi: 10.1186/s13046 -017-0558-5.


Joffre C, Djavaheri-Mergny M, Pattingre S, Giuriato S. The yin and the yang of autophagy in cancer cells. Med Sci (Paris). 2017 Mar;33(3):328-334. doi: 10.1051 /medsci/20173303021.


Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. Eur J Cancer. 2017 Mar 8;76:68-75. doi: 10.1016/j.ejca.2017.02.003. [Epub ahead of print]


Lehmann-Che J, Poirot B, Boyer JC, Evrard A. La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision. Therapie. 2017 Jan 3. pii: S0040-5957(16)31284-7. doi: 10.1016/j.therap.2016.09.009. [Epub ahead of print]


Lehmann-Che J, Poirot B, Boyer JC, Evrard A. Cancer genomics guide clinical practice in personalized medicine. Therapie. 2017 Jan 30. pii: S0040-5957(17)30007-0. doi: 10.1016/j.therap.2016.09.015. [Epub ahead of print]


Marzi L, Combes E, Vié N, Ayrolles-Torro A, Tosi D, Desigaud D, Perez-Gracia E, Larbouret C, Montagut C, Iglesias M, Jarlier M, Denis V, Linares LK, Lam EW, Martineau P, Del Rio M, Gongora C. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.313. [Epub ahead of print]


Dalloneau E, Baroukh N, Mavridis K, Maillet A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, Castaneda DC, Dhommée C, Arnoult C, Scorilas A, Gouilleux-Gruart V, Heuzé-Vourc'h N.Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget. 2016 Jun 15. doi: 10.18632/ oncotarget.10074. [Epub ahead of print]


Mbatchi LC, Robert J, Ychou M, Boyer JC, Del Rio M, Gassiot M, Thomas F, Tubiana N, Evrard A. Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.Clin Pharmacokinet. 2016 Apr 26. [Epub ahead of print]


Roubaud G, Brouste V, Beuzeboc P, Fléchon A, Tosi D, Lavau-Denes S, Chevreau C, Culine S, Oudard S, Quivy A, Pourquier P, Houédé N. Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. J Negat Results Biomed. 2015 Nov 10;14(1):18.


Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, Lavigne JP, Allaouchiche B, Lefrant JY, Roberts JA, Muller L. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
J Antimicrob Chemother. 2015 Oct 1. [Epub ahead of print]


Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. Ann Oncol. 2015 Sep 14. [Epub ahead of print] Review.


Bach AS, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, Theillet C, Gongora C, Pattingre S, Ibing E, Roger P, Linares LK, Reinheckel T, Meurice G, Kaiser FJ, Gespach C, Liaudet-Coopman E. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells.
Oncotarget. 2015 Sep 29;6(29):28084-103.


Mbatchi LC, Schmitt A, Thomas F, Cazaubon Y, Robert J, Lumbroso S, Brouillet JP, Pourquier P, Chatelut E, Boyer JC, Evrard A. Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics. 2015 Aug;16(13):1439-50. Epub 2015 Aug 12.


Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean- Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015 Jul;16(7):787-94. Epub 2015 May 28.


Chakiba C, Cornelis F, Descat E, Gross-Goupil M, Sargos P, Roubaud G, Houédé N. Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. Eur J Radiol. 2015 Jun;84(6) :1023-8.  Epub 2015 Mar 6..

Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, Houéde N, Roy C, Durand X, Varinot J, Vordos D, Rouanne M, Bakhri MA, Bertrand P, Jeglinschi SC, Cussenot O, Soulié M, Pfister C. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015 May; 466(5): 589-94.  Epub 2015 Feb 20.


Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, Del Conte G, Durigova A, Hayaoui N, Gourgou S, Gianni L, Mollevi C. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies. J Clin Oncol. 2015 May 26. pii: JCO.2014.58.1082. [Epub ahead of print]


Westover D, Ling X, Lam H, Welch J, Jin C, Gongora C, Del Rio M, Wani M, Li F. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance. Mol Cancer. 2015 Apr 28;14:92.


Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015 Apr; 16(4):417-25.  Epub 2015 Mar 3.


Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, Topart D, Roubaud G, Agherbi H, Rebillard X, Azria D Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer. 2015 Apr 4;15(1):222


Houédé N, Leutenegger E, Lomma M, Bellera C. Formal Consensus Method to Evaluate the Conformity of Prescription of a Recently Approved Chemotherapy Treatment in an Observatory Study. PLoS One. 2015 Apr 2;10(4):e0123035. doi: 10.1371/journal.pone.0123035. eCollection 2015.


Antoine V, de Wazières B, Houédé N. [Professional's expectations to improve quality of care and social services utilization in geriatric oncology]. Bull Cancer. 2015 Feb;102(2): 150-61. Epub 2015 Jan 30. French.


Houédé N, Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther. 2015 Jan;145:1-18. Epub 2014 Jun 12. Review.


Houédé N, Pulido M, Mourey L, Joly F, Ferrero JM, Bellera C, Priou F, Lalet C, Laroche-Clary A, Raffin MC, Ichas F, Puech A, Piazza PV. A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer. Oncologist. 2014 Dec;19(12):1227-8.

Sebti S, Prébois C, Pérez-Gracia E, Bauvy C, Desmots F, Pirot N, Gongora C, Bach AS, Hubberstey AV, Palissot V, Berchem G, Codogno P, Linares LK, Liaudet-Coopman E, Pattingre S. BAT3 modulates p300-dependent acetylation of p53 and autophagy-related protein 7 (ATG7) during autophagy. PNAS. 2014 Mar 18;111(11):4115-20.

Thierry AR MF, El Messaoudi S, Rolet F, Gongora C, Robert B, Del Rio M, Mollevi C,  Lamy PJ, Lopez-Crapez E, Bibeau F, Loriot V, Molina F, Mathonnet M, Pezet D,  and  Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23


Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger SW, Gonzalez Ostos LC, Lannon WA, Del Rio M, Lhermitte B, Olshen AB, Cantley LC, Gray JW, Hanahan D. A Colorectal Cancer Classification System that Associates Cellular Phenotype and Responses to Therapy.  Nature Medecine. 2013. 19(5):619-25.


Mazard T, Causse A, Simony J, Evrard A, Leconet W, Vezzio-Vie N, Jarlier M, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, Gongora C. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. Molecular Cancer Therapeutics. 2013 Oct;12(10):2121-34

Del Rio M, Mollevi C, Vezzio-Vie N, Bibeau F, Ychou M, Martineau P.  Specific extracellular matrix remodeling signature of colon hepatic metastases. PLoS One. 2013 Sep 4;8(9):e74599

Puyo S, Houede N, Kauffmann A, Richaud P, Robert J, Pourquier P (2012) Gene expression signature predicting high-grade prostate cancer responses to oxaliplatin. Mol Pharmacol. 82: 1205-1216

Paillas S., Causse A., Marzi L., De Medina P., Poirot M., Denis V., Vezzio-Vie N., Espert L., Arzouk H, Coquelle A., Martineau P., Del Rio M., Pattingre S. and Gongora C. MAPK14/p38alpha confers Irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy. 2012. 8(7).

Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M and Gongora C. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Research. 2011 Feb 1;71(3):1041-9.

Raynal C, Pascussi JM, Leguelinel G, Breuker C, Kantar J, Lallemant B, Poujol S, Bonnans C, Joubert D, Hollande F, Lumbroso S, Brouillet JP, Evrard A (2010) Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 9: 46.



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés